A Phase 1 interventional study of Comparator: sitagliptin phosphate and Comparator: pioglitazone in Type 2 Diabetes Mellitus (T2DM), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 68th largest by enrollment of the 197 interventional ones that give a count, is one of 17 that started in 2007, is one of 23 in phase 1, and was the 32nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 30 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 81st largest by enrollment of the 170 interventional ones that give a count, is one of 19 that started in 2007, is one of 55 in phase 1, and was the 29th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A clinical study to determine the safety, efficacy and mechanism of action of sitagliptin alone and in combination with pioglitazone, in patients with type 2 diabetes mellitus who have inadequate glycemic (blood sugar) control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: drug
Drug: Comparator: sitagliptin phosphate · Drug: Comparator: placebo to pioglitazone
Arm 2: active comparator
Drug: Comparator: pioglitazone · Drug: Comparator: placebo to sitagliptin
Arm 3: drug + active comparator
Drug: Comparator: sitagliptin phosphate · Drug: Comparator: pioglitazone
Arm 4: placebo comparator
Drug: Comparator: placebo to pioglitazone · Drug: Comparator: placebo to sitagliptin
sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
Change From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment
Glucagon concentration was measured at 9 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, and 180 minutes. Total AUC was calculated over 3 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.
Time frame: Baseline and 12 weeks
Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment
Static sensitivity is a measure of the effect of glucose on beta cell secretion and is the ratio between the insulin secretion rate and glucose concentration above the threshold level at steady state. Percent change from baseline was calculated as the difference between index of static sensitivities at Week 12 and at baseline with respect to the index of static sensitivity at baseline times 100.
Time frame: Baseline and 12 weeks
Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment
Glucose concentration was measured at 11 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, 180, 240, 300 minutes. Total AUC was calculated over 5 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.
Time frame: Baseline and 12 weeks
First Patient In: 12-Sep-2007; Last Patient Last Visit: 24-Feb-2009 Forty-four medical clinics worldwide (17 in the United States, 20 in Europe, 4 in Australia, and 3 in Israel).
| Milestone | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo |
|---|---|---|---|---|
| Started | 52 | 54 | 52 | 53 |
| Completed | 46 | 52 | 47 | 48 |
| Not completed | 6 | 2 | 5 | 5 |
| Withdrew: Adverse event | 2 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 0 | 3 | 2 |
Glucagon concentration was measured at 9 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, and 180 minutes. Total AUC was calculated over 3 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.
| pg*hr/mL | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment | -17.2 (-30.1 to -4.2) | -4.9 (-18.1 to 8.3) | -29.8 (-43.6 to -16.1) | 12.5 (-1.9 to 26.9) |
Static sensitivity is a measure of the effect of glucose on beta cell secretion and is the ratio between the insulin secretion rate and glucose concentration above the threshold level at steady state. Percent change from baseline was calculated as the difference between index of static sensitivities at Week 12 and at baseline with respect to the index of static sensitivity at baseline times 100.
| Percent Change | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo |
|---|---|---|---|---|
| Percent Change From Baseline in Index of Static Beta-cell Sensitivity to Glucose After 12 Weeks of Treatment | 71.5 (46.8 to 100.3) | 27.0 (7.8 to 49.7) | 125.2 (87.2 to 171.0) | -2.3 (-17.4 to 15.5) |
Glucose concentration was measured at 11 points during an Meal Tolerance Test (MTT), at times -10, 0, 10, 20, 30, 60, 90, 120, 180, 240, 300 minutes. Total AUC was calculated over 5 hours including all sample points starting from 0 minutes using the trapezoid method. The change from baseline reflects Week 12 total AUC minus the Week 0 total AUC.
| mg*hr/dL | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Glucose 5-hour Total AUC After 12 Weeks of Treatment | -209.8 (-281.6 to -138.0) | -245.6 (-316.6 to -174.6) | -389.2 (-463.6 to -314.7) | 18.6 (-58.2 to 95.4) |
Collected over Weeks 0-12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg | — | 1/52 (1.9%) | 3/52 (5.8%) |
| Pioglitazone 30 mg | — | 0/54 (0%) | 3/54 (5.6%) |
| Sitagliptin 100 mg + Pioglitazone 30 mg | — | 1/52 (1.9%) | 0/52 (0%) |
| Placebo | — | 0/53 (0%) | 9/53 (17%) |
| Event | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo |
|---|---|---|---|---|
| Tibia fractureInjury, poisoning and procedural complications | 0/52 | 0/54 | 1/52 | 0/53 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/52 | 0/54 | 0/52 | 0/53 |
| Event | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo |
|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 3/52 | 0/54 | 0/52 | 0/53 |
| Upper respiratory tract infectionInfections and infestations | 0/52 | 3/54 | 0/52 | 3/53 |
| Blood glucose increasedInvestigations | 0/52 | 0/54 | 0/52 | 3/53 |
| HeadacheNervous system disorders | 0/52 | 0/54 | 0/52 | 3/53 |
| Age, Continuous(years) | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 54.6 ± 7.6 | 53.4 ± 7.8 | 53.3 ± 8.6 | 53.3 ± 7.7 | 53.6 ± 7.9 |
| Sex: Female, Male(Participants) | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 24 | 31 | 18 | 21 | 94 |
| Male | 28 | 23 | 34 | 32 | 117 |
| Race/Ethnicity, Customized(participants) | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo | Total |
|---|---|---|---|---|---|
| White | 45 | 43 | 49 | 48 | 185 |
| Black | 6 | 9 | 3 | 2 | 20 |
| Asian | 1 | 1 | 0 | 2 | 4 |
| Other | 0 | 1 | 0 | 1 | 2 |
| Glucose 5-hour (hr) Total area under the curve (AUC)(mg*hr/dL) | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 1179.9 ± 322.8 | 1250.6 ± 349.6 | 1276.0 ± 348.5 | 1255.1 ± 290.9 | 1240.4 ± 328.4 |
| Hemoglobin A1c (HbA1c)(Percent) | Sitagliptin 100 mg | Pioglitazone 30 mg | Sitagliptin 100 mg + Pioglitazone 30 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 7.7 ± 0.8 | 7.9 ± 0.9 | 7.9 ± 0.9 | 8.0 ± 1.1 | 7.9 ± 1.0 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jul 2007 to primary completion in Feb 2009, 19 months.
Results were first posted in Mar 2010, 1 year after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 19 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Pioglitazone